Davis Capital Management
IART icon

Davis Capital Management’s Integra LifeSciences IART Stock Holding History

Davis Capital Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-4
Closed -$72 – 1263
2026
Q2 		$72 Buy
+4
New +$56 ﹤0.01% 1142

Other funds holding IART

Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $551B AUM 33.95% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
LSV Asset Management
LSV Asset Management Chicago, Illinois $54.1B AUM 39.29% 1-Year Est. Return
Access Investment Management
Access Investment Management Atlanta, Georgia $412M AUM 14.18% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Leeward Investments
Leeward Investments Boston, Massachusetts $1.98B AUM 28.98% 1-Year Est. Return
Principal Financial Group
Principal Financial Group Des Moines, Iowa $195B AUM 21.17% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 33.83% 1-Year Est. Return
Commonwealth Equity Services
Commonwealth Equity Services Waltham, Massachusetts $77B AUM 19.24% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return

Davis Capital Management's IART Position: Q3 2026 in Review

Davis Capital Management sold out of Integra LifeSciences (IART) in Q3 2026, closing a stake of 4 shares — an estimated $72 sold.

Davis Capital Management first reported a position in IART in Q2 2026 and held it in 1 quarter. The position peaked at $72 in Q2 2026. 86 funds tracked by Wall St. Rank hold IART as of Q3 2026.

  • Davis Capital Management reported no remaining Integra LifeSciences position as of Q3 2026 after selling out during the quarter.
  • Davis Capital Management sold 4 Integra LifeSciences shares in Q3 2026, an estimated $72.
  • Davis Capital Management first reported a position in Integra LifeSciences in Q2 2026 and held it in 1 quarter.
  • Davis Capital Management's Integra LifeSciences position peaked at $72 in Q2 2026.
  • 86 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2026.

Based on Davis Capital Management's 13F filing for Q3 2026, filed 8 Oct 2026.